OncoMatch/Clinical Trials/NCT07283835
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Is NCT07283835 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cretostimogene Grenadenorepvec for non muscle invasive bladder cancer.
Treatment: Cretostimogene Grenadenorepvec — This study aims to evaluate the efficacy and safety of Cretostimogene in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta/T1 papillary tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage CIS (TNM)
Excluded: Stage ANY N
Grade: high-grade
BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without concomitant Ta/T1 papillary disease
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: BCG
BCG-unresponsive
Cannot have received: systemic anti-cancer therapy
Has received systemic anti-cancer therapy, including investigational agents.
Cannot have received: systemic treatment (with the exception of checkpoint inhibitor therapy)
Exception: checkpoint inhibitor therapy
Has had prior systemic treatment (with the exception of checkpoint inhibitor therapy), radiation therapy, or surgery for bladder cancer other than TURBT or bladder biopsies.
Cannot have received: radiation therapy
Has had prior systemic treatment (with the exception of checkpoint inhibitor therapy), radiation therapy, or surgery for bladder cancer other than TURBT or bladder biopsies.
Cannot have received: surgery for bladder cancer other than TURBT or bladder biopsies
Has had prior systemic treatment (with the exception of checkpoint inhibitor therapy), radiation therapy, or surgery for bladder cancer other than TURBT or bladder biopsies.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07283835 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anti-cancer therapy, systemic treatment (with the exception of checkpoint inhibitor therapy), radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage CIS is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages